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Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Hucknall Road, Nottingham NG5 1PB, England, UKLower respiratory tract infections (LRTIs), including pneumonia, are
a leading cause ofmortality globally. In 2013, an estimated 708,600 chil-
dren aged 1 to 5 years of age died from LRTIsmaking it themain killer in
this age group; approximately 99% of these deaths occurred in develop-
ing countries. (Nair et al., 2013; GBD2013Mortality andCauses of Death
Collaborators, 2015).
In developed countries, the burden of pneumonia falls more heavily
on older persons with annual incidence rates of pneumonia-related
hospitalisations of over 60 per 10,000 for adults aged 65 to 79 years, in-
creasing to over 160 per 10,000 for adults aged 80 years and older (Jain
et al., 2015). Over the next decade, further changes in the population
age structure globally anticipate increases in susceptible persons.
Given such large health implications, commensurate investments in
basic and translational research to tackle this problem are warranted. In
this Journal, Head and colleagues report on funding awarded to UK insti-
tutions for pneumonia research from 1997 to 2013 (Head et al., 2015).
Their report updates results arising from the Research Investments in
Global Health study which previously described data up to 2010 (Head
et al., 2014).
The proportion of funding for pneumonia in relation to all respiratory
infectious research was 6.8% (£27.8 million) over the period 1997–2010
and increased to 19.9% (£28.8 million) over the period 2011–2013. The
areas of greatest relative increase were in Global Health (16.6%; £4.6 mil-
lion to 60.45%; £17.4million) andDiagnostics (1.2%; £0.3million to 23.6%;
£6.8 million). These increases are welcomed and are consistent with the
efforts of the World Health Organisation and funding bodies, such as
The Bill &Melinda Gates Foundation, to address the problemof childhood
pneumonia in resource-poor settings (Adegbola, 2012).
In contrast, a decrease in funding for Antimicrobial Resistance from
10.4% (£2.9 million) over the period 1997–2010 to 0.01% (£0.004 mil-
lion) over the period 2011–2013 was noted. This is an unexpected ﬁnd-
ing in the context of the high priority set by theUKChiefMedical Ofﬁcer,
Sally Davies, in relation to the problem of antimicrobial resistance
(Davies et al., 2013). Many of the so-called “ESKAPE” pathogens
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spe-
cies) that demonstrate multi-drug resistance are respiratory pathogens
associated with hospital-acquired pneumonia (Boucher et al., 2009).
Further investigation may yield explanations for this apparent reversal
in pneumonia research investment related to antimicrobial resistance.DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.06.024.
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and colleagues have tried to map research investment to research out-
put using bibliometrics, speciﬁcally the total number of publications re-
lated to pneumonia across the study period. Understandably, an
absolute count of publications does not adequately reﬂect research
quality. Elaborate methods for the evaluation of research quality, akin
to the UK national Research Excellence Framework (REF), are currently
available. However, even these sophisticated approaches have their
own deﬁciencies (Wooding et al., 2015). More consistent and interna-
tionally validated methods are awaited. The impact of research funding
on advances in clinical practice is potentially evenmore difﬁcult tomea-
sure. For instance, the absence of major differences between 2009 and
2014 in British national guideline recommendations for the manage-
ment of adult community-acquired pneumonia hints at a lack of sub-
stantive advances in the related evidence base over that period (Lim
et al., 2015). Is this due simply to a deﬁciency in relevant research in-
vestment? It can, of course, take many years for pre-clinical research
to bear fruit at the bedside. In this respect, the relative increase in trans-
lational pneumonia research observed by Head and colleagues in 2011–
2013 compared to earlier years hopefully presages concrete advances in
clinical management in the near future.
In the meantime, the increase in pneumonia research funding be-
tween 2011 and 2013 compared to 1997 and 2010 is not a reason for
complacency. Relative to the burden of disease, funding for pneumonia
research is still at a lower level compared to funding for tuberculosis and
inﬂuenza. In 1898, in the 3rd edition of The Principles and Practice of
Medicine, Sir William Osler wrote of lobar pneumonia that it “is the
most fatal of all acute diseases.….. So fatal is it in this country, at least,
that one may say that to die of pneumonia is the natural end of old people”.
Sir Osler was writing at a time when doctors and patients did not have
the beneﬁt of antimicrobial agents nor vaccines. His words should not
be taken to engender a sense of nihilism in relation to themodernman-
agement and investigation of pneumonia. The work by Head and col-
leagues is valuable not simply for its description of funding already
awarded, but lends direction to funders and researchers in the pursuit
of further research that will contribute towards the control of this
dreaded illness in persons of all ages.Declaration of Interest
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